I-Mab operates as a clinical stage biopharmaceutical company. It engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zhang Zang on June 30, 2016 and is headquartered in Pudong, China. The listed name for IMAB is I-MAB American Depositary Shares.